Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
OrforglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist, FDA-approved April 2026. No injections, no fasting restrictions. The ATTAIN-1 trial showed 12.4% average weight loss at 72 weeks, though GI side effects run higher than comparable injectable GLP-1 drugs.
0.8mcg · Daily
Summary: Add 0mL BAC water to your 45mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.8mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.8mg | Daily |
| Moderate | 5.5mg | Daily |
| Aggressive | 17.2mg | Daily |
Oral tablet. No vials, no syringes, no reconstitution math. That alone makes orforglipron the simplest GLP-1 drug to start. Titration schedule matters more than most beginners realize. You start at 0.8 mg daily for a full 30 days before moving to 2.5 mg. Then 5.5 mg for another 30 days. After that, you can escalate to 9 mg, 14.5 mg, or 17.2 mg based on how your body responds. Skipping steps or rushing the schedule significantly increases nausea and GI side effects. The detail that catches people off guard: if you miss 7 or more consecutive doses, you restart the entire titration from 0.8 mg. Not from where you left off. Swallow the tablet whole. Don't crush, break, or chew it. Take it any time of day, food or no food, water or no water. No awkward 30-minute fasting window like Rybelsus. Constipation hits harder than most expect (30% in trials). Start extra fiber and fluids on day 1, not after symptoms appear. Each dose escalation step tends to bring a fresh wave of nausea for 5 to 7 days; plan increases during low-stress weeks.
Dosing based on Foundayo (orforglipron) FDA Prescribing Information (2025) — 8 published references.View all sources →
Cross-check your Orforglipron reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist, FDA-approved April 2026. No injections, no fasting restrictions. The ATTAIN-1 trial showed 12.4% average weight loss at 72 weeks, though GI side effects run higher than comparable injectable GLP-1 drugs.
